Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
224.9 USD | +2.21% | +3.27% | -13.07% |
31.05. | Europäische Kommission erteilt Marktzulassung für ALS-Medikament von Biogen | RE |
30.05. | Biogen erhält Zulassung der Europäischen Kommission für Qalsody | MT |
ETFs investiert in Biogen Inc.
Name | Gewichtung | Volumen | % 1. Jan. | Investm. Rating |
---|---|---|---|---|
0,21% | 32 M€ | +1.01% | - | |
0,21% | 17 M€ | +5.27% | - | |
0,20% | 1 448 M€ | -.--% | - | |
0,20% | 219 M€ | +17.17% | - | |
0,20% | 50 M€ | +8.95% | ||
0,20% | 330 M€ | -.--% | ||
0,20% | 2 M€ | +14.69% | - | |
0,18% | 368 M€ | +21.35% | - | |
0,18% | 8 M€ | +5.45% | - | |
0,18% | 744 M€ | +8.16% | ||
0,18% | 276 M€ | +11.40% | - | |
0,18% | 273 M€ | -.--% | ||
0,18% | 655 M€ | -.--% | - | |
0,18% | 1 174 M€ | +23.54% | ||
0,17% | 36 M€ | +22.19% | ||
0,17% | 253 M€ | +5.88% | ||
0,16% | 26 M€ | +21.33% | - | |
0,15% | 2 383 M€ | +13.18% | ||
0,14% | 559 M€ | +14.30% | ||
0,14% | 1 848 M€ | +18.39% | - | |
0,13% | 1 M€ | +0.04% | ||
0,12% | 6 M€ | +17.98% | - | |
0,12% | 121 M€ | +7.93% | - | |
0,12% | 2 M€ | +5.21% | - | |
0,12% | 17 M€ | +4.00% | - | |
0,12% | 205 M€ | -.--% | ||
0,11% | 57 M€ | +21.00% | - | |
0,10% | 264 M€ | -.--% | - | |
0,10% | 187 M€ | +9.30% | - | |
0,10% | 477 M€ | +11.68% |
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
-13.07% | 32.75 Mrd. | |
-2.29% | 89.87 Mrd. | |
-3.95% | 37.57 Mrd. | |
+63.05% | 26.47 Mrd. | |
-22.14% | 14.25 Mrd. | |
-7.96% | 12.99 Mrd. | |
-9.33% | 11.93 Mrd. | |
-46.33% | 10.84 Mrd. | |
+5.77% | 9.11 Mrd. | |
-17.66% | 7.32 Mrd. |
- Börse
- Aktien
- 789617 Aktie
- ETFs Biogen Inc.